

TEL : 0091- 217 - 2310824  
: 0091- 217 - 2451500  
FAX : 0091- 217 - 2451521  
E-MAIL : info@balajiamines.com  
WEBSITE : http://www.balajiamines.com

*Balaji*



ISO 9001:2015



www.tuv.com  
ID 9105038797

CIN : L24132MH1988PLC049387

## AMINES LIMITED

REGD. OFF. : 'BALAJI TOWERS'  
No. 9/1A/1, HOTGI ROAD,  
AASARA CHOWK, SOLAPUR - 413 224.  
MAHARASHTRA. (INDIA)

3<sup>rd</sup> February, 2020

To,  
The General Manager-Department of Corporate  
Services,  
BSE Limited  
Phiroze Jeejebhoy Towers,  
Dalal Street, Mumbai – 400 001.

The Manager-Listing Department,  
National Stock Exchange of India Limited,  
"Exchange Plaza", 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra-Kurla Complex,  
Bandra(East), Mumbai – 400 051

**Scrip Code: 530999**

**Scrip Code: BALAMINES**

Dear Sir,

**Sub: Investor Presentation**


Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are enclosing herewith the Updated Investor Presentation.

The Investor Presentation is also being uploaded on the website of the Company at the URL <http://www.balajiamines.com/investor-relations>

Please take same on the record.

Thanking You,

Yours faithfully,  
**For Balaji Amines Limited**

  
**D. Ram Reddy**  
Managing Director





# Balaji Amines Limited



Investor Presentation – February 2020

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Balaji Amines Limited (the “Company”)**, have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.


This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

# Q3FY20: Performance Highlights

## Revenue (Rs. Crore)

## EBITDA (Rs. Crore)


## PAT (Rs. Crore)




\*Note – Q2FY20 PAT was higher on account of revision in corporate tax rate

# 9MFY20: Performance Highlights


### Revenue (Rs. Crore)



### EBITDA (Rs. Crore)



### PAT (Rs. Crore)





Total volumes stood at 21,160 MT for Q3FY20 as against 19,128 MT in Q3FY19

- Amines volumes stood at 4,732 MT
- Amines Derivatives volumes stood at 8,547 MT
- Specialty Chemicals volumes stood at 7,881 MT

Q3FY20 EBITDA margins improved viz-a-viz Q2FY20 margins, on account of better product mix, improvement in volume offtake and the resultant increase in operating leverage

Pharmaceutical sector's performance is expected to improve on the domestic front with the onset of winter season. Also the pricing pressure in the USA has eased. However, increased scrutiny of the US Food and Drug Administration on some plants is likely to delay some product launches for a few companies

Agrochemical sector's prospects are likely to brighten on account of higher storage across reservoirs coupled with the recent price hike in minimum support price

Recently, made an application to Government of India for levying anti-dumping duties on Dimethylformamide (DMF). Witnessed better pricing of DMF which has increased the viability of the manufacturing of the same. Expect gradual improvement in capacity utilization to 65% from around ~20% levels

**Received the environmental clearance for our 90-acre Greenfield Project.** In the phase-1 of the Greenfield Project of Unit 4, the company will install capacity for manufacturing 16,500 tons of Ethyl Amines and 9,900 tons of Dimethyl Carbonate (DMC). The capex involved is estimated at Rs. 150-170 crore, which will be largely funded by internal accruals. **Post the commencement of the phase-1 project, the company will have the largest installed capacity of Ethyl Amines in India at 22,500 tons per annum**

# Standalone Statement of Profit & Loss

Particulars (in Rs. Crore)	Q3FY20	Q3FY19	Y-o-Y	Q2FY20	Q-o-Q	9MFY20	9MFY19	Y-o-Y
<b>Revenue from Operations</b>	<b>224.1</b>	<b>240.0</b>	<b>-6.6%</b>	<b>233.3</b>	<b>-4.0%</b>	<b>691.1</b>	<b>718.5</b>	<b>-3.8%</b>
Raw Material	119.6	139.5		128.1		389.1	394.5	
<b>Gross Profit</b>	<b>104.4</b>	<b>100.5</b>	<b>3.9%</b>	<b>105.2</b>	<b>-0.7%</b>	<b>302.0</b>	<b>324.0</b>	<b>-6.8%</b>
<b>Gross Profit Margin</b>	<b>46.6%</b>	<b>41.9%</b>		<b>45.1%</b>		<b>43.7%</b>	<b>45.1%</b>	
Employee expense	14.0	12.1		11.5		36.2	37.5	
Other expenses	44.6	44.7		45.1		132.0	137.0	
<b>EBITDA</b>	<b>45.8</b>	<b>43.7</b>	<b>4.8%</b>	<b>48.6</b>	<b>-5.7%</b>	<b>133.8</b>	<b>149.5</b>	<b>-10.5%</b>
<b>EBITDA Margin</b>	<b>20.4%</b>	<b>18.2%</b>		<b>20.8%</b>		<b>19.4%</b>	<b>20.8%</b>	
Other Income	0.0	0.0		0.0		0.0	0.0	
Depreciation	5.7	4.7		5.8		16.5	14.2	
<b>EBIT</b>	<b>40.1</b>	<b>39.0</b>	<b>2.8%</b>	<b>42.8</b>	<b>-6.2%</b>	<b>117.3</b>	<b>135.4</b>	<b>-13.3%</b>
<b>EBIT Margin</b>	<b>17.9%</b>	<b>16.3%</b>		<b>18.3%</b>		<b>17.0%</b>	<b>18.8%</b>	
Finance Cost	2.9	3.5		3.8		9.3	9.8	
Exceptional Items	0.0	0.0		0.0		0.0	0.0	
<b>Profit before Tax</b>	<b>37.2</b>	<b>35.5</b>	<b>4.9%</b>	<b>39.0</b>	<b>-4.6%</b>	<b>108.0</b>	<b>125.6</b>	<b>-14.0%</b>
<b>PBT Margin</b>	<b>16.6%</b>	<b>14.8%</b>		<b>16.7%</b>		<b>15.6%</b>	<b>17.5%</b>	
Tax	10.5	9.2		4.3		26.6	34.5	
<b>Profit after Tax</b>	<b>26.7</b>	<b>26.3</b>	<b>1.8%</b>	<b>34.7*</b>	<b>-23.0%</b>	<b>81.4</b>	<b>91.1</b>	<b>-10.6%</b>
<b>PAT Margin (%)</b>	<b>11.9%</b>	<b>10.9%</b>		<b>14.9%</b>		<b>11.8%</b>	<b>12.7%</b>	
<b>EPS (in Rs.)</b>	<b>8.25</b>	<b>8.11</b>		<b>10.71</b>		<b>25.12</b>	<b>28.11</b>	


\*Note – Q2FY20 PAT was higher on account of revision in corporate tax rate




About Us




# Amines Industry – Small but Critical Industry with growth potential




# Balaji Amines Ltd – A Leading player in Aliphatic Amines in India



**Largest manufacturer of Aliphatic Amines in India**



**State-of-the-art manufacturing facilities fully equipped with latest DCS technology**



**25+ Product basket**



**Zero Liquid Discharge facilities**

**Only Company in the World to develop an Indigenous Technology to manufacture Amines**



### Stringent Domestic & International Quality Standards

- ISO 9001: 2015 certified Company
- REACH certified products to regulated markets in Europe
- WHO-GMP certificate to export its products to regulated international markets



**Strong Global presence**

**INDIAN MULTINATIONAL**



### Forward integrated suite of products

Downstream products added based on strength of amine manufacturing which have value addition and cost advantage




### Installed Capacity

**1,84,500 MTPA**

# Our Products are supplied to India's fast-growing Industries

INDUSTRY WISE – REVENUE BREAKUP



- Pharma
- Agrochem
- Paints & Resins
- Animal Feeds
- Oil & Gas
- Rubber Cleaning Chemicals
- Water Treatment Chemicals
- Dye and Textiles
- Others



PHARMA



AGRO-CHEMICALS



ANIMAL FEEDS



PAINTS & RESINS



OIL & GAS



RUBBER CLEANING CHEMICALS



WATER TREATMENT CHEMICALS



DYES & TEXTILES

# Highly Experienced Management Team



**Mr. A. Srinivas Reddy**

**Whole Time Director**

- Post Graduate in Computer Science and completed Executive Management Programme at ISB Hyderabad.
- More than 21 years experience in multiple Project Management Roles
- He is presently responsible for projects

**Mr. D. Ram Reddy**

**Managing Director**

- 30 years of experience across various businesses.
- Focused on establishing customer and supplier's relationship with leading buyers and suppliers
- Responsible for the supply chain, sales and marketing

**Mr. A. Pratap Reddy**

**Executive Chairman**

- Civil Engineer by Education. Incorporated BAL in 1988
- BAL's continuing success is a testimony to his entrepreneurial skills.
- His vision has made BAL today as one of the leading players in chemical industry.

**Mr. N. Rajeshwar Reddy**

**Joint Managing Director**

- B. Com. Over 40 years of experience across industries
- Instrumental in project commissioning with indigenous approach to improve return profile
- Responsible for operations in Solapur

**Mr. G. Hemanth Reddy**

**Whole Time Director & CFO**

- Post Graduate in management with Finance and Marketing as specialization.
- More than 25 years of experience
- Responsible for finance, operations & administration along with Hyderabad Operations



## Amines

## Amine Derivatives

## Specialty & Other Chemicals

### Description

- Aliphatic Amines find increasing consumption and applications in a Chemically mature Industry such as India, Europe, US, China and Japan
- The Aliphatic Amines industry is expected to grow at a CAGR of 5%-7%

- Amine Derivatives are used to make further salts and other complex chemical Intermediates and API's
- In derivatives, Di-Methyl Amine Hydrochloride (DMA HCL) is one of BAL's key product offerings.

- Albeit a small and fastest growing segment
- Within specialty chemicals, is the single-largest product in specialty chemicals.

### Products

- Mono Methyl Amine (MMA)
- Di-Methyl Amine (DMA)
- Tri-Methyl Amine (TMA)
- Mono-Ethyl Amine (MEA)
- Di-Ethyl Amine (DEA)
- Tri-Ethyl Amine (TEA)
- Di-Methyl Amino Ethanol (DMAE)
- Di-Ethyl Amino Ethanol (DEAE)

- Di-Methyl Acetamide (DMAC)
- Di-Methyl Amine Hydrochloride (DMA HCL)
- Tri-Methyl Amine Hydrochloride (TMA HCL)
- Mono-Methyl Amine Hydrochloride (MMA HCL)
- Di-Ethyl Amine Hydrochloride (DEA HCL)
- Tri-Ethyl Amine Hydrochloride (TEA HCL)
- Mono-Ethyl Amine Hydrochloride (MEA HCL)
- Di-Methyl Urea (DMU)
- Choline Chloride

- Morpholine
- Acetonitrile
- Dimethylformamide (DMF)
- N-Ethyl-2-Pyrrolidone (NEP)
- 2-Pyrrolidone (2-P)
- Gamma Butyrolactone,
- N-Methyl-Pyrrolidone (NMP)
- Pharmapure Povidone (PVP K30 & PVP K25)

### Application

- Pharma
- Agro
- Photographic chemicals
- Rocket fuel
- Dyestuff intermediates
- Rubber chemicals, etc

- Pharma
- Pesticides
- Performance chemicals
- Specialty chemicals
- Animal/poultry feed additive etc.

- Production of Water Treatment chemicals and pesticide formulations
- Solvents across industries like pharmaceuticals, petrochemicals, dyes, Agro and paint industries

## Amines



## Amine Derivatives




## Specialty & Other Chemicals



# Well positioned Business Model aimed at Sustainable growth

Focus towards high-value derivatives and specialty chemicals with an aim to move up the value-chain with vertical integration

Develop new indigenous technology for manufacturing products leading to lowering in manufacturing costs & improving of return ratios



Focus on R&D to introduce new products, improve systems and processes that drive efficiencies

Cater to fast growing industries, namely, pharmaceuticals, agro-chemicals, refineries, water treatment, rubber, electronics, dye stuff and paints, animal feed, photographic chemicals and leather processing

Strategize investments towards products which are substantial imports or products with limited competition

**Business Strategy to achieve**

**Robust growth**

+

**Sustain healthy margins**

+

**Improve return ratios**

# Key Products (Current & Proposed) in Portfolio

## Balaji Amines

In MTPA

Product	Installed Capacity	Future Capacity	Application Areas
Methyl Amine	48,000	-	Pharma, Agro, Dye & Rubber
Ethyl Amine	6,000	16,500	Pharma, Agro, Dye & Rubber
DMAHCL	25,000	7,500	Pharma
DMAC	6,000	-	Pharma API
Choline Chloride 60% (Corn Cob)	6,000	-	Animal Feed
Choline Chloride 75% & 98%	6,000	-	Animal Feed
2P / NEP	33,000	-	Pharma, Agro, Petro, Dyes, Paints
NMP		-	Pharma, Agro, Petro, Dyes, Paints
GBL		-	Pharma, Agro, Petro, Dyes, Paints
DMU	2,000	-	Pharma, Textile, Agro
DMAE / DEAE	2,000	-	Cosmetics
Morpholine	10,000	-	Pharma, Agro, Dyes, Paints, Textile, Rubber
Other HCL'S	750	-	Animal Feed
DMF	30,000	-	Pharma, Agro, Polymers, Petro, Dyes, Paints
Acetonitrile	9,000	9,000	Pharma, Petro, Textile, Plastics
PVP K-30	750	-	Pharma, Agro, Cosmetics
Tetra Hydro Furan	-	8,000	Pharma API Agro
Di-methyl Carbonate (DMC)	-	9,900	Pharma, Polycarbonate, Automobiles
<b>Total</b>	<b>1,84,500</b>	<b>41,900</b>	

## Balaji Speciality Chemicals

In MTPA

Product	Installed Capacity	Application Areas
Ethylenediamine	37,350	Pesticides, Polymers
Piprazine	4,050	Pharma, Oilfield
Diethyltriamine	3,150	Coatings, Polymers, Pharma
Mixture of Amines (Aminoethylpiperzine / Hydroxyethylpiperzine / Aminoethylethanolamine, etc.)	780	Multiple Industries
<b>Total</b>	<b>45,330</b>	

**Proven Product Portfolio with few products manufactured for the 1<sup>st</sup> time in India**



# We are Global suppliers – a significant validation of our Capabilities



**20.79% of the Total Revenue of Rs. 943 Crore for FY 2019 is generated from exports spanning across continents**


# Awards & Certificates – A Testimony of our capabilities



ISO Certificate



Two Star Export House



ISO Certificate



Certificate of Merit – CHEMEXCIL



First Award – CHEMEXCIL




ISO 9001 : 2015 Certificate



WHO GMP Certificate



REACH Pre-Registration



Niryat Shree Award by FIEO



Product Innovator of the Year in Chemicals - 2018



**“Long-Term Issuer Rating affirmed at ‘IND AA-’ by India Ratings and Research (Ind-Ra).” The ratings process highlighted the following factors:-**

- 
- Largest manufacturer of aliphatic amines and their derivatives in India
  - Increased product offtake and meaningful contribution from BSCPL from FY21 onwards
  - New project capex undertaken to add new products and drive growth
  - Sole producer for a few specialty chemicals insulates company from the competition
  - Ability to maintain healthy and stable EBITDA margins
  - Ability to pass on raw material price volatility to its customers
  - End product selection policy based on import substitution, and to be the first or second domestic manufacturers of products
  - Diversified portfolio of over 25 products
  - Ability to generate operating cash flow to remain strong in the medium term

# High entry barrier Business – Paving way for Sustainable growth



## Complex Manufacturing

Complex manufacturing process requiring high levels of technological know-how. Efficient producers with wide product range emerge winners



## High Lead time

Niche product offering with high lead time in customer approvals



## Capex Heavy Business

High fixed costs, with fixed asset turns hovering in the range of 1.5-2x. Optimum capacity utilization is paramount to sustain profitability over a long period of time



## R&D led Innovation is key

R&D focus to introduce new products for import substitutes for Indian market



## High Volume Continuous Process

Continuous process ensures better efficiencies as compared to batch process but adds to complexity that cannot be easily replicated



## Stringent Government Regulations

Hazardous nature of the Process requires environmental clearances



# Well positioned Business Model aimed at Sustainable growth



## Value-Added Products

Capex towards high-value derivatives and specialty chemicals will materialize into higher revenue and enhanced margins

01



## Applicability in Solvents segment

Solvents account for 80%-90% of the mass utilised in a typical pharmaceutical chemical operation


05



## Specialization in logistics

Aliphatic Amines have huge handling risk and hence it is difficult to transport them, which reduces the threat of imports

02



## Consumed by bulk drug companies

Methyl Amines and derivatives, utilized by bulk drugs players, are expected to continue to see a surge in demand

06



## Preference for Local Sourcing

Safety is a critical factor and hence end-users prefer to work with only local 2-3 credible suppliers

03



## Huge potential in agrochemical markets

The agrochemicals market in India is expected to be a \$10.6 bn market by FY2020 with nearly 55% exports – Aliphatic Amines to be key beneficiary

07



## Exposure to pharma sector

Extensive usage in solvents led to significant exposure of Aliphatic Amines in the pharma segments; Growth of Pharma sector to benefit Amines Industry

04



## Vertical and Horizontal Integration

Vertical and horizontal integration has enabled BAL to maintain a dominant position in a majority of its products through the dual advantage of cost competitiveness and product switching flexibility

08

# Greenfield Project to fuel growth and add Revenue Visibility



## Strategically Located Plant

**Environmental clearance received for Greenfield Project on a 90-acre land in Solapur, Maharashtra.** Strategically located to customers in western & southern India



## Mega Project Status

Phase-1 of Greenfield Project expected to **commence production in Q4FY21**; Project accorded Mega Project Status




## Project Capex

**Project cost of Rs. 150-170 Crs** of Phase-1 to be funded entirely by Internal Accruals




## Product Profile

Plan to Manufacture **50 TPD Ethyl Amines** and **30 TPD Di-methyl Carbonate (DMC)** in Phase-1



## Indigenous Technology

Plan to deploy Indigenous technology resulting in higher Asset Turns; Established customer base for products leading to faster break-even



## New Products = 1<sup>st</sup> mover advantage


Significant opportunity exists to introduce new products & gain 1<sup>st</sup> mover advantage




## High Demand for Products

**High demand** exists for **DMC** which is currently fully met by imports. Import substitution is key opportunity in addition to inherent domestic demand & exports opportunity for DMC

# Balaji Speciality Chemicals – Production commenced in H2FY20




# R&D led Investments to provide significant early mover advantage




## New Products

Identification of new products and development of latest process technologies



## Environment Conscious

Waste water treatment and minimization of effluents by adopting Industry best practices for effluent treatment.




## Optimization

Continuous efforts to optimize utilization of energy, utilities & raw materials consumption and alternate routes to drive efficiencies



## Efficiency

Continuous efforts in all plants have delivered lowest consumption coefficients in the Industry for BAL products



## Integration

Backward and forward integration of products to improve value chain and better utilization of all the resources



## Sustainability

Through Continuous efforts For sustainable usage of natural resources, the Company has initiated various models in reducing, reusing and recycling of various natural resources



## Hotel Division




# Balaji Sarovar Premiere – Best in class Business Hotel in Solapur



## Balaji Sarovar Premiere (Solapur)

# Balaji Sarovar Premiere – At a Glance

- Commenced Operations in October 2013 Hotel Balaji Sarovar Premier is the only 5 star hotel in Solapur
- Invested Rs. 110 crore in the Hotel Project via mix of Debt and Equity
- Tied up with Sarovar Group for the Management of the Hotel on Management Fee + Revenue Share model
- Solapur is an important Tourist hub owing to its close proximity to Pandharpur, Tuljapur, Siddeshwar Temple, Ganagapur, Bijapur and Akkalkot
- Solapur attracts millions of Tourists and pilgrims every year



**Hotel project has resulted in substantial cash flow savings**

# Balaji Sarovar Premiere – Operating Matrix (FY19)



129 Rooms



Constitutes 2.2% of Total Revenue



Rs. 3,375 ARR



63% Occupancy Rate

**Balaji  
Sarovar  
Premiere**



Negligible Routine Capex incurred



RS. 2,133 RevPAR



Renowned Five Star Hotel In the City of Solapur

ARR : Average Room Revenue  
RevPAR: Revenue per Available Room







# Financial Performance

# Consolidated Performance Highlights


### Revenue (Rs. Crs.)




### EBITDA (Rs. Crs.)




### PAT (Rs. Crs.)




### EBITDA Margin (%)



### PAT Margin (%)



### RoE (%)





# Strong Core RoCE Profile

Particulars (Rs. Crs.)	FY19
Standalone Debt	94.6
Standalone Networth	575.0
<b>Total Capital Employed</b>	<b>669.6</b>
Less: Investment in Hotel Balaji Sarovar	133.3
Add: Loss in Hotel Balaji Sarovar	48.7
Less: Investments/Loan in Balaji Speciality	98.9
Less: Investments in Greenfield project (Unit 4)	22.0
<b>Core Chemical Business Capital Employed (A)</b>	<b>464.1</b>
EBIT on Standalone Basis	179.1
Less: EBIT Specific to Hotel Project	1.6
<b>Core Chemical Business EBIT (B)</b>	<b>180.7</b>
<b>ROCE for Core Chemical Business (B/A)</b>	<b>38.92%</b>
ROCE on Standalone Basis	26.74%

- Investments made to the tune of Rs. 98.90 crs. in Subsidiary of Balaji Amines and Rs. 22 crs. in Greenfield project (Unit 4) not considered as the commercialization of the same is expected in FY20 and FY21 respectively
- Core Chemical Business RoCE is significantly higher depicting the inherent strength of the Business and capabilities developed in product manufacturing
- Capex in Subsidiary and Greenfield project (Unit 4) to start contributing to Revenues and profitability from FY20 and FY21 onwards respectively

# Consolidated Profit & Loss Account


Consolidated P&L (Rs. Cr)	FY19	FY18	YoY
<b>Revenue from Operations</b>	<b>943.1</b>	<b>861.2</b>	<b>9.5%</b>
Raw Material	515.4	464.1	
<b>Gross Profit</b>	<b>427.7</b>	<b>397.1</b>	<b>7.7%</b>
<b>Gross Profit Margin</b>	<b>45.4%</b>	<b>46.1%</b>	
Employee Cost	48.3	45.1	
Other Expenses	186.0	162.6	
<b>EBITDA</b>	<b>193.4</b>	<b>189.5</b>	<b>2.1%</b>
<b>EBITDA Margin</b>	<b>20.5%</b>	<b>22.0%</b>	
Other Income	4.2	4.1	
Depreciation	19.6	19.3	
<b>EBIT</b>	<b>178.1</b>	<b>174.3</b>	<b>2.2%</b>
<b>EBIT Margin</b>	<b>18.9%</b>	<b>20.2%</b>	
Finance Cost	13.0	9.0	
Exceptional Item Gain / Loss	3.6	0.6	
<b>Profit before Tax</b>	<b>168.6</b>	<b>165.8</b>	<b>1.7%</b>
<b>PBT Margin</b>	<b>17.9%</b>	<b>19.3%</b>	
Tax	51.5	52.7	
<b>PAT</b>	<b>117.1</b>	<b>113.2</b>	<b>3.5%</b>
<b>PAT Margin %</b>	<b>12.4%</b>	<b>13.1%</b>	
<b>EPS (in Rs.)</b>	<b>36.1</b>	<b>34.9</b>	

# Consolidated Balance Sheet Statement

ASSETS (Rs. Crore)	Mar-19	Mar-18
<b>(1) NON-CURRENT ASSETS</b>		
(a) Property, plant & equipment	319.7	316.1
(b) Capital work-in-progress	269.5	123.1
(c) Intangible Asset		
(d) Financial assets		
(i) Investments		
(ii) Loans		
(iii) Other Financial Assets	4.0	3.8
(e) Deferred Tax Asset		
(f) Other Non - current assets	3.1	50.1
<b>Sub Total (A)</b>	<b>596.3</b>	<b>493.1</b>
<b>(2) CURRENT ASSETS</b>		
(a) Inventories	163.2	89.1
(b) Financial Assets		
(i) Investments		
(ii) Trade receivables	167.2	172.7
(iii) Cash and cash equivalents	14.5	2.2
(iv) Bank Balances other than (iii) above	6.1	21.9
(v) Other Financial Assets		
(c) Current tax assets (net)	53.3	54.1
(d) Other current assets	45.3	14.6
<b>Sub Total (B)</b>	<b>449.6</b>	<b>354.7</b>
<b>Total Assets (A+B)</b>	<b>1045.9</b>	<b>847.8</b>

EQUITY AND LIABILITIES (Rs. Crore)	Mar-19	Mar-18
<b>EQUITY</b>		
(a) Equity Share capital	6.5	6.5
(b) Other equity	567.5	460.6
(c) Non-Controlling Interest	18.0	18.0
<b>Sub Total (C)</b>	<b>592.0</b>	<b>485.1</b>
<b>LIABILITIES</b>		
<b>(1) Non-Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	83.3	42.5
(ii) Trade Payables	13.2	12.8
(iii) Other Financial Liabilities excl. provisions	3.2	0.6
(b) Provisions		
(c) Deferred Tax Liabilities (Net)	45.8	50.2
(d) Other Non-Current Liabilities		
<b>Sub Total (D)</b>	<b>145.5</b>	<b>106.0</b>
<b>(2) Current Liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	107.2	99.7
(ii) Trade Payables	85.3	71.8
(iii) Other Financial Liabilities excl. provisions	37.4	10.0
(b) Other current liabilities		
(c) Provisions	22.6	22.0
(d) Current Tax Liabilities (Net)	56.0	53.3
<b>Sub Total (E)</b>	<b>308.4</b>	<b>256.7</b>
<b>Total Equity &amp; Liabilities (C+D+E)</b>	<b>1045.9</b>	<b>847.8</b>

# Consistent Dividend Payout



Particulars (Rs. per share)	FY15	FY16	FY17	FY18	FY19
Consolidated Book Value	71.0	88.9	111.9	149.7	182.7
Consolidated EPS	11.2	18.9	26.4	34.9	36.4
Dividend	1.2	2.0	2.2	2.6	2.8



Moving to Version 2.0



### Capex Phase

Greenfield Capex to be completed till 2021 will result in 50% increase in revenue base by 2022-23

### Brownfield Expansion


Moving to higher margin niche products such as THF and NEP will result in stable to positive up move in Margin profile

### Subsidiary Expansion

Manufacturing of new products such as Ethylene Diamine, Piperazine and Diethylenetriamine in Balaji Speciality Chemicals to provide strong boost to product profile

### Greenfield

Expansion and commercialization of 90-acre project in MIDC Chincholi to focus on manufacturing new products to address the increasing demand for value added amine derivatives



**Brownfield Expansion & Greenfield Capex + Subsidiary Expansion =  
Balaji Amines Ltd : Version 2.0**

For further information, please contact:

Company :



Balaji Amines Ltd.  
CIN - L24132MH1988PLC049387  
Email - [info@balajiamines.com](mailto:info@balajiamines.com)  
[www.balajiamines.com](http://www.balajiamines.com)

Investor Relations Advisors :

**SGA** Strategic Growth Advisors

Strategic Growth Advisors Pvt. Ltd.  
CIN - U74140MH2010PTC204285  
Mr. Shogun Jain / Mr. Parin Narichania  
[shogun.jain@sgapl.net](mailto:shogun.jain@sgapl.net) / [parin.n@sgapl.net](mailto:parin.n@sgapl.net)  
+91 77383 77756 / +91 99300 25733  
[www.sgapl.net](http://www.sgapl.net)